BACKGROUND The staging of axillary lymph nodes is critical to the management and prognosis of breast cancer, the most frequent cancer in females. Neoadjuvant therapy and lymph node dissection are recommended when malignant cells invade the lymph nodes. Therefore the pre-operative examination of these lymph nodes is crucial to treatment. METHODS In this study, we examined the effectiveness of ...

The purpose of this study was to assess whether breast cancer subtype (BCS) as determined by estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 can predict the axillary lymph node metastasis in breast cancer. Patients who received breast conserving surgery or mastectomy and axillary lymph node dissection were identified from 2 cancer centers. The associations...

BACKGROUND The arm lymphedema is reported as being the most frequent late reaction and complication that influences breast cancer patients'€™ quality of life after lymph node dissection and radiotherapy. The aim of the study is to identify the risk factors in arm lymphedema occurrence in breast cancer patients who performed radical conservatory surgery, chemotherapy and radiotherapy. MATERIAL...

The detection of regional lymph node metastases is important in cancer staging as it guides the prognosis of the patient and the strategy for treatment. Sentinel lymph node biopsy (SLNB) is an accurate, less invasive alternative to axillary lymph node dissection. The sentinel lymph node hypothesis states that the pathological status of the axilla can be accurately predicted by determining the s...

BACKGROUND Seroma formation following modified radical mastectomy with axillary lymph node dissection for breast cancer is a most common wound complication. In our experience seroma occurs in approximately 50% of patients undergoing mastectomy. Postmastectomy seromas usually vanishes within a few weeks after operation. CASE PRESENTATION In this report we present the case of a 73 year old woma...

Administering adjuvant irradiation to the level III axilla and supraclavicular fossa (SCF) is indicated for those patients who undergo the standard level I-II axillary dissection and who have four or more positive axillary nodes or T3-4 primary disease.(1-3) The risk of failure in the axillary apex or SCF is less than 5% for the patients who have T1-2 primary tumors and fewer than 4 involved ax...